tirzepatide and seizures associated autoimmune encephalitis: A case report Tirzepatide and Heart Palpitations: Is

Archived (PDF) from the original on 5 May 2020

When to seek medical advice for injection site issues

Contact your GP or diabetes specialist nurse if you experience: Persistent insomnia lasting more than 23 weeks despite implementing sleep hygiene measures Severe gastrointestinal symptoms that significantly disrupt sleep and daily functioning Symptoms of hypoglycaemia , particularly nocturnal episodes, including night sweats, palpitations, confusion upon waking, or morning headaches Excessive daytime fatigue that interferes with work, driving, or daily activities Mood changes including low mood, anxiety, or irritability that may be related to poor sleep quality Unexplained weight loss exceeding expected therapeutic targets New or worsening visual symptoms , especially if you have existing diabetic retinopathy, as rapid improvement in blood glucose can temporarily worsen retinopathy [14] [15] Seek urgent medical attention if you develop: Signs of severe dehydration from vomiting or diarrhoea (reduced urination, dizziness, confusion), which can lead to acute kidney injury Severe, persistent abdominal pain, particularly if accompanied by vomiting Symptoms of pancreatitis (severe upper abdominal pain radiating to the back) Call 999 for severe hypoglycaemia with confusion, loss of consciousness, or seizures Contact NHS 111 for urgent but non-life-threatening concerns Your healthcare team can assess whether your sleep problems are related to Ozempic or other factors

From Phase 3 start to final obesity approval was roughly four years, and from NDA submission to first approval was about seven months under priority review

Scan-to-verify reports linked directly to your vials batch number

Because retatrutide is not yet licensed in the UK, anyone currently taking it should be doing so within a clinical trial or specialist research programme, with a named clinician or research team overseeing their care